The Outlook at Two Years
“The results over the two years are that pegylated interferon beta-1a has a positive effect on relapse rate and disease progression beyond the one-year placebo-controlled study period,” Dr. Calabresi said. “Over the two years, we saw a benefit of being on continuous pegylated interferon beta-1a, compared to the delayed treatment group. There were continued significant differences in many of the outcome measures in the two-week dosing group, as compared to the four-week dosing group.”
—Glenn S. Williams